News

Community Engagement through Drama

Dr. Gill Black

Listen to Gill Black Podcast

Summary: Dr. Gill Black is the co-founder and Director of Health and Welfare at The Sustainable Livelihoods Foundation (SLF). In this inteview, we discuss with Dr. Black one of SLF’s groundbreaking projects that uses drama to engage local communities around issues related to TB and HIV/AIDS. The goal of the foundation is to contribute towards eliminating poverty through undertaking original research and engaging with communities to develop and advance innovative approaches to strengthening livelihoods. SLF undertakes several projects to achieve its objectives:

  • To undertake path-breaking, state of the art, pragmatic research into the constraints and obstacles to human development and make this knowledge accessible to a wider audience, through simplification and audio and visual communication
  • To undertake creative public engagement with communities, learning of their challenges and equipping them with knowledge and skills to foster resilience and strengthen their livelihood opportunities
  • To conceptualize and pioneer innovative development practice to influence policy and programs and to apply these ideas through micro-projects to demonstrate their effectiveness and sustainability

Sustainable Livelihood Foundation Gallery

More News
9 Jul 2020
Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the...
18 Jun 2020
On May 21st, Antimicrbial Agents and Chemotherapy published an article on Otsuka's novel anti-tuberculosis compound, OPC-167832. This molecule, a DprE1 inhibitor, demonstrated potent bactericidal activity and exhibited significant combination effects in 2-drug combinations with delamanid,...
17 Jun 2020
On March 25th, Qurient announced the results of their Phase 2 Clinical Trial (ClinicalTrials.gov number, NCT03563599 ), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed...